Assessment of the frequency of cardiovascular risk factors in patients with Takayasu's arteritis

Rheumatology (United Kingdom)

Volumn 56, Issue 11, 2017, Pages 1939-1944

  Alibaz Oner, Fatma ^a,b   Koster, Matthew J ^a   Unal, Ali U ^b   Yildirim, Hale G ^b   Çikikçi, Ceylan ^b   Schmidt, Jean ^c   Crowson, Cynthia S ^a   Makol, Ashima ^a   Ytterberg, Steven R ^a   Matteson, Eric L ^a   Direskeneli, Haner ^b   Warrington, Kenneth J ^a  

^a MAYO CLINIC   (United States)

^b MARMARA UNIVERSITY   (Turkey)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Atherosclerotic risk; Cardiovascular event; Takayasu's arteritis

Indexed keywords

ANTILIPEMIC AGENT; CORTICOSTEROID;

ADULT; AORTIC ARCH SYNDROME; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TURKEY (REPUBLIC); BODY MASS; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; DIABETES MELLITUS; DYSLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; OBESITY; RISK FACTOR; SMOKING; TAKAYASU ARTERITIS; TURKEY; UNITED STATES; YOUNG ADULT;

ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TAKAYASU ARTERITIS; TURKEY; UNITED STATES; YOUNG ADULT;

EID: 85032790718     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex300     Document Type: Article

References (33)

1. Alibaz-Oner F, Aydin SZ, Direskeneli H. Advances in the diagnosis, assessment and outcome of Takayasu's arteritis. Clin Rheumatol 2013;32:541-6
2. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56:1000-9
3. Schmidt J, Kermani TA, Bacani AK et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 2013;88:822-30
4. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196-202
5. Han C, Robinson DW Jr, Hackett MV et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72
6. Elfving P, Puolakka K, Kautiainen H et al. Mortality and causes of death among incident cases of systemic lupus erythematosus in Finland 2000-2008. Lupus 2014;23:1430-4
7. Cohen Tervaert JW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol 2013;27:33-44
8. Tervaert JW. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol 2009;15:377-85
9. Cohen Tervaert JW. Cholesterol and modifications of cholesterol in rheumatic disorders. In: Hoffman GS, Weyand CM, Langford CA, Gorozny JJ, eds. Inflammatory Diseases of Blood Vessels, 2nd edn. Oxford: Wiley-Blackwell, 2012, 475-83
10. Ungprasert P, Koster MJ, Warrington KJ. Coronary artery disease in giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2015;44:586-91
11. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996;100:193-6
12. Ninan J, Nguyen AM, Cole A et al. Mortality in patients with biopsy-proven giant cell arteritis: a south australian population-based study. J Rheumatol 2011;38:2215-7
13. Tomasson G, Peloquin C, Mohammad A et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis. A cohort study. Ann Intern Med 2014;160:73-80
14. Seyahi E, Ugurlu S, Cumali R et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006;65:1202-7
15. de Souza AW, Ataíde Mariz H, Torres Reis Neto E et al. Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patients. Clin Rheumatol 2009;28:379-83
16. da Silva TF, Levy-Neto M, BonfáE, Pereira RM. High prevalence of metabolic syndrome in Takayasu arteritis: increased cardiovascular risk and lower adiponectin serum levels. J Rheumatol 2013;40:1897-904
17. Arend WP, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-34
18. D'Agostino RB Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53
19. Perk J, De Backer G, Gohlke H et al. ; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635-701
20. Hata A, Noda M, Moriwaki R et al. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 1996;54(Suppl):S155-63
21. de Souza AW, Machado NP, Pereira VM et al. Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J 2010;74:1236-41
22. Liu Q, Dang A, Lv N, Wang X, Zheng D. Anaemia and low body mass index are associated with increased cardiovascular disease in patients with Takayasu arteritis. Clin Exp Rheumatol 2016;34(Suppl. 97):S16-20
23. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26
24. Hotchi M. Pathological studies on Takayasu arteritis. Heart Vessels Suppl 1992;7:11-7
25. Rose AG, Sinclair-Smith CC. Takayasu's arteritis: a study of 16 autopsy cases. Arch Pathol Lab Med 1980;104:231-7
26. Alibaz-Oner F, Yurdakul S, Aytekin S, Direskeneli H. Impaired endothelial function in patients with Takayasu's arteritis. Acta Cardiol 2014;69:45-9
27. Akazawa H, Ikeda U, Yamamoto K, Kuroda T, Shimada K. Hypercoagulable state in patients with Takayasu's arteritis. Thromb Haemost 1996;75:712-6
28. Watanabe T, Kishi Y, Numano F, Isobe M. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis. Thromb Res 2001;104:77-83
29. De Souza AW, De Lima CS, Oliveira AC et al. Homocysteine levels in Takayasu arteritis-a risk factor for arterial ischemic events. J Rheumatol 2013;40:303-8
30. de Carvalho JF, BonfáE, Bezerra MC, Pereira RM. High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis. Clin Rheumatol 2009;28:801-5
31. Numano F. Vasa vasoritis, vasculitis and atherosclerosis. Int J Cardiol 2000;75(Suppl 1):S1-8
32. Selvarajah S, Kaur G, Haniff J et al. Comparison of the Framingham Risk Score, SCORE and WHO/ISH cardiovascular risk prediction models in an Asian population. Int J Cardiol 2014;176:211-8
33. Chen L, Tonkin AM, Moon L et al. Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart. Eur J Cardiovasc Prev Rehabil 2009;16:562-70